- Trial phase
- Phase 2
- Time to market
- Not estimable. The Phase 2 MSA study was discontinued for futility; the broader program's future is uncertain.
- Why 3/10
- The next hard catalyst for emrusolmin was the Phase 2 TOPAS-MSA topline readout, but that catalyst arrived today (Nov 2, 2026) with a negative outcome: the study was discontinued after an interim futility analysis. No new dated binary catalyst is scheduled. For a large, diversified pharma like Teva, this single mid-stage pipeline asset is a modest part of the overall enterprise value, so the impact score is low.
The Phase 2 TOPAS-MSA study was discontinued today (Nov 2, 2026) after an interim futility analysis, removing emrusolmin as a near-term pipeline catalyst. Teva says this is not a final decision on the broader program and will analyze open-label extension data, but no further development path or timeline has been outlined. For a diversified pharma like Teva, this is a modest pipeline setback; watch for any update on whether the Parkinson's disease program continues.
Price Chart
Executive Summary
Emrusolmin (TEV-56286 / Anle138b) was an oral small-molecule inhibitor of alpha-synuclein aggregation being developed by Teva Pharmaceutical Industries (NYSE: TEVA) for Multiple System Atrophy (MSA), a rare and fatal neurodegenerative disease with no approved disease-modifying treatments. It had FDA Fast Track and Orphan Drug designations, and Teva had guided to peak sales potential exceeding $2 billion. On November 2, 2026, Teva announced it was discontinuing the Phase 2 TOPAS-MSA study after a pre-specified interim futility analysis indicated a low probability of meeting the primary efficacy endpoint. No safety concerns were identified. The stock fell approximately 5.6% in pre-market trading. Teva stated the decision does not represent a final verdict on the broader emrusolmin program and will analyze open-label extension data, but no clear development path forward has been outlined.
How It Works
Emrusolmin is an oral small-molecule drug designed to block the clumping (aggregation) of a protein called alpha-synuclein in the brain. In diseases like Multiple System Atrophy (MSA) and Parkinson's disease, alpha-synuclein misfolds and forms toxic clumps that kill nerve cells. Emrusolmin aims to stop this process, potentially slowing or halting disease progression.
Trial Status
The Phase 2 TOPAS-MSA study (NCT06568237) was discontinued on November 2, 2026, following an interim futility analysis. A separate open-label extension study (NCT07197866) continues to evaluate long-term safety in patients who completed the 48-week treatment period. Emrusolmin also has a Phase 1/2 trial in Parkinson's disease, but its status is unclear following the MSA futility result.
The Two-Sided Case
Upcoming Catalysts
- Analysis of open-label extension data from the TOPAS-MSA study (no date set)
- Potential update on the Parkinson's disease Phase 1/2 program (no timeline given)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Teva Pharmaceutical Industries Ltd Press Release TEVA ·Originating report